Trials / Unknown
UnknownNCT05595993
Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache
Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache: A Randomized Clinical Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Danish Headache Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To investigate whether cilostazol (phosphodiesterase 3 inhibitor) induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol | Study participants will be allocated to receive oral administration of 200 mg cilostazol. |
| DRUG | Placebo | Study participants will be allocated to receive oral administration of placebo. |
Timeline
- Start date
- 2022-10-25
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2022-10-27
- Last updated
- 2023-02-08
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05595993. Inclusion in this directory is not an endorsement.